Abstract-In many hypertensive patients, treatment is not upgraded despite lack of blood pressure control because of therapeutic inertia. Information is limited, however, on the extent of this phenomenon in real-life medicine. We studied 125 635 patients (age 40-85 years) from the Lombardy region (Italy) who started antihypertensive treatment with 1 drug (n=100 982) or a 2-drug fixed-dose or free combination (n=24 653). A log-binomial regression model was used to estimate the prevalence ratio of combination therapy in relation to the initial treatment strategy. In the initial monotherapy group, patients under drug combinations were 22%, 27%, 32%, and 36% at 6 months, 1, 2, and 3 years later. In the initial combination treatment group, the corresponding percentages were 85%, 82%, 79%, and 78%. This translated into a markedly greater covariate-adjusted propensity of being under a multidrug prescription throughout the follow-up: 3.92 (95% CI, 3.84-4.00) after 6 months and 3.18 (3.12-3.25), 2.56 (2.51-2.60), and 2.23 (2.19-2.27) after 1, 2 and 3 years of treatment. In a propensity score analysis, initial 2-drug combination treatment was also associated with significant reductions in the risk of death (−20%, 11% to 28%) and hospitalization for cardiovascular events (−16%, 10% to 21%) compared with initial monotherapy. Thus, in real life, a large number of patients prescribed initial monotherapy fails to move to combination treatment, as recommended by guidelines. This implies that therapeutic inertia frequently prevents proper treatment uptitration, thereby playing a major role in the low rate of hypertension control that exists worldwide. (Hypertension. 2018;72:846-853.
vidence has been obtained that compared with initial monotherapy, starting antihypertensive treatment with 2 drugs is accompanied by a more frequent long-term blood pressure (BP) control, that is, a greater number of patients in whom BP control is achieved months or years later. 1 This may be explained by the observation that compared with initial monotherapy, initial administration of 2 antihypertensive drugs is associated with a better long-term adherence to the prescribed treatment regimen, 2, 3 possibly because the prompter BP reduction provided by 2 antihypertensive drugs favourably affect patients' confidence in the effectiveness of treatment and compliance with the physician's recommendations. 4 Another possible factor, however, is that starting treatment with 2 drugs may prevent therapeutic inertia, namely failure of upgrading treatment from 1 drug to drug combination even if drug combination is known to be necessary to reach the recommended BP target in most patients. [5] [6] [7] [8] In the present study, the importance of therapeutic inertia was addressed by determining how many patients starting antihypertensive treatment with a single drug moved to combination treatment in the following years, as recommended by hypertension guidelines. 9 The study was performed in a population-based cohort, made available by the healthcare utilization database of the entire Lombardy population. Patients starting treatment with a 2-drug combination were used as the control group.
Methods
The data that support the findings of this study are available from Lombardy Region, but restrictions apply to the availability of these data, which were used under license for the current study and so are not publicly available. Data are, however, available from the authors on reasonable request and with permission of Lombardy Region.
Setting
The data used for this study were retrieved from the healthcare utilization databases on the residents of Lombardy, a Region of Italy that accounts for ≈16% (10 million) of its population. The Italian population is covered by the National Health Service that provides hospitalization, major diagnostic procedures, and so-called life-saving drugs (including antihypertensive agents) to all citizens free or almost free of charge. In Lombardy, an automated system of databases has been created to collect information on the effectiveness and cost of the National Health Service performance. For each patient, we linked the information provided by these archives through a single identification code. To preserve the privacy of the beneficiaries, identification codes were deidentified, and the conversion table was deleted. Details on use of the Lombardy databases for research on cardiovascular diseases have been reported elsewhere. 3, 10, 11 
Cohort Selection
The target population included Lombardy residents, aged 40 to 85 years, who were beneficiaries of the National Health Service. Of these, those who received at least 1 antihypertensive drug prescription during 2008 were identified, and the first dispensation was defined as the index prescription. Exclusion regarded patients who (1) had received antihypertensive drug prescriptions within 3 years before the index prescription to focus the study on newly treated patients, (2) had been hospitalized for cardiovascular disease or received drugs for coronary heart disease or heart failure (eg, digitalis and nitrates) within the 8 years before the index prescription to limit data collection to the setting of primary cardiovascular prevention, (3) were initially prescribed ≥3 drugs, and (4) did not reach at least 6 months of follow-up after the index prescription and thus could not even contribute to calculation of the earliest outcome (see below). The remaining patients were included into the final cohort whose members were followed from the date of the index prescription until censoring, that is, death, emigration, or 3 years after the index prescription.
Drug Exposure
Cohort members were classified according to initial antihypertensive treatment strategy, that is, whether monotherapy or combination of 2 antihypertensive drugs given separately or in a single fixed-dose tablet was dispensed at the index prescription. From the index prescription date, the antihypertensive drugs dispensed during the following 3 years were identified and the drug prescribed at 6 months, 1, 2, and 3 years after the index prescription was used for the study purposes (see below).
Covariates
Baseline data included patients' age and sex, as well as cotreatments with cardiovascular and noncardiovascular drugs. Information extended to comorbidities based on hospitalization for cardiovascular and noncardiovascular diseases during the 8-year period before the index prescription. Patients' clinical status was further assessed by the Multisource Comorbidity Score, a new prognostic index derived from 34 diagnostic and therapeutic items available in the databases of Lombardy and other Italian regions, which has recently been found to be a more sensitive predictor of survival than other largely used scores.
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Outcome Evaluation
The primary goal of the study was to compare how many patients were on multidrug treatment for hypertension during the follow-up according to whether they were initially prescribed monotherapy or 2-drug free or fixed-dose combination therapy. Secondary goals were (1) to compare how many patients from the 2 groups were prescribed more than 2 drugs during the follow-up, (2) to determine the percentage of patients remaining on mono or 2-drug combination treatment during the entire follow-up period who switched to, respectively, a mono or combination therapy different from the initial one, and (3) to compare the risk of hospitalization for cardiovascular events (ie, heart failure, ischemic heart disease, and cerebrovascular disease) and death between the 2 groups, that is, patients under initial monotherapy and combination therapy.
To this aim, all antihypertensive drugs dispensed during the follow-up were identified and the number of available agents prescribed at 6 months, 1, 2, and at 3 years after the index prescription date were evaluated. For each time-point, the closest preceding or following prescription was considered. In line with previous analyses, 2,3 if no prescription was available for >90 days around a time-point (45 days before and 45 after the time-point), patients were considered as treatment discontinuers. Furthermore, death for any causes and hospitalization for cardiovascular events as the primary diagnosis were recorded for the whole 3-year follow-up for all cohort members.
Data Analysis
The t test, χ 2 test and its version for the trend were used, when appropriate, to test differences in demographic, clinical, and therapeutic characteristics between different patient groups. Log-binomial regression models were fitted to estimate the prevalence ratio and its 95% CI, of combination therapy at the above-mentioned times (ie, 6 months, 1, 2, and 3 years of follow-up) in relation to the initial treatment strategy, using monotherapy as reference. Adjustments were made for the aforementioned baseline covariates.
Furthermore, 3 sensitivity analyses were performed. One, because the clinical profile of patients under initial mono or 2-drug combination therapy was not superimposable, data were also analyzed according to the high-dimensional propensity score method, 13 using the above-mentioned information (see the Covariates section) plus those automatically selected from the archives of prescriptions and hospitalizations in the 2-year period before the date of the index prescription. The aim of high-dimensional propensity score algorithm is to empirically identify the variables strongly associated with the exposure and outcome. We decided to select the 200 most prevalent empirical covariates. For each patient in the initial combination treatment group, 1 patient under initial monotherapy was randomly selected from the cohort to be matched for high-dimensional propensity score (±0.01). In this way, 2 groups equal for size and a large number of variables were formed. Two, because during a hospitalization no information on drug prescription was available, the drugs prescribed immediately before hospital admission were regarded as prescribed also during the hospital stay. This avoided the so-called immeasurable bias, 14 as well as an overestimation of the study population who was under no antihypertensive drugs. Three, to match the 2 groups for the class of antihypertensive drugs prescribed, the comparison was limited to patients prescribed a monotherapy a diuretic or a blocker of the renin-angiotensin system and a combination (mostly as fixed-dose single tablet) between a blocker of the renin-angiotensin system and a diuretic, that is, by far the most widely used initial combination. Other recommended fixed-dose combinations, such as those between a blocker of the renin-angiotensin system and a calcium channel blocker were not included in the database because they were not reimbursable by the National Health Service.
To evaluate the relationship between initial antihypertensive treatment strategy and the risk of death and cardiovascular events, the Cox proportional-hazards model was fitted to estimate the hazard ratio for the effect of initial mono and combination therapy on these outcomes. The model was used after matching the 2 groups according to the above-mentioned high-dimensional propensity score method. To further increase the initial between-group homogeneity, data for combination therapy were analyzed only for fixed-dose combinations, which were also by far the most widely used initial combination treatment strategy.
All analyses were performed using the Statistical Analysis System Software (version 9.4; SAS Institute, Cary, NC). For all hypotheses tested, 2-tailed P values <0.05 were considered to be significant.
Results
Patients
As shown in Figure 1 , among the large number of patients who were prescribed antihypertensive drugs in 2008, 125 635 patients met the inclusion criteria and represented the study cohort. Of these, ≈80% started treatment with 1 drug and ≈20% with a free or fixed-dose combination of 2 drugs. The most frequent monotherapy was by far a renin-angiotensin system blocker (51% of the patients) followed by a β-blocker, a diuretic and a calcium channel blocker, whereas for most patients the initial fixed-dose 2-drug combination was that between a blocker of the renin-angiotensin system and a diuretic (93% of the patients; Table S1 in the online-only Data Supplement). Table 1 shows that, compared with patients under initial monotherapy, patients prescribed an initial combination therapy were slightly older, more frequently male, and less frequently cotreated with most cardiovascular or noncardiovascular drugs. Comorbidities were also slightly less common in the initial combination treatment group, which also showed a slightly better clinical profile at the Multisource Comorbidity Score.
Number of Antihypertensive Drugs During Follow-Up
In a large number of patients, there was no antihypertensive drug prescription at the time-points selected for data analysis, reflecting treatment discontinuation. In the initial monotherapy group, patients under no prescription were 45%, 46%, 45%, and 44% after 6 months, 1, 2, and 3 years, respectively. The corresponding figures were significantly, albeit moderately, less in the initial 2-drug combination treatment group, that is, 41% (P<0.001), 42% (P<0.001), 41% (P<0.001), and 41% (P<0.001).
As shown in Figure 2 , in the initial monotherapy group use of drug combinations increased during the follow-up time, but single drug prescription remained by far the most common treatment, the percentage of patients under monotherapy ranging from about three-fourths to two-thirds of the total group between the 6 months and the 3 years of follow-up. In contrast, although in a number of patients treatment was downgraded to monotherapy, in the initial 2-drug combination group 2-drug treatment remained by far the most common treatment type. This group also showed a twice more frequent use of ≥3 antihypertensive drugs and an overall chance of being prescribed drug combinations (2+ drugs) that was always more than double the use of combination treatment in the initial monotherapy group. When estimates were adjusted for available covariates (see Methods), patients on initial combination therapy showed a significant and marked increase in the propensity of being on combination treatment than patients under initial monotherapy (Figure 3) . The increase ranged from almost 4 to >2× after 6 months to 3 years of follow-up, with values that were always slightly but significantly greater (P value always <0.001) with initial use of a fixed-dose (n=19 627) versus a free combination (n=5026) when these 2 groups were separately compared with initial monotherapy ( Table 2) .
As shown in the Figure S1 , similar findings were obtained when comparisons were made between initial combination therapy with a diuretic and a blocker of the renin-angiotensin system (by far the most frequent initial combination) and an initial diuretic or renin-angiotensin system blocker monotherapy. Furthermore, the propensity of being prescribed a combination treatment in relation to the initial treatment strategy did not change either by applying the high-dimensional propensity score algorithm and by accounting for the immeasurable time bias (Table S2 ). Figure S2 shows that in patients remaining on monotherapy during the entire follow-up period, changes from one monotherapy to another increased with time but were by and large infrequent, that is, ≈1 in 7 patients after 6 months and 1 in 3 patients after 3 years. This was the case also in patients remaining on combination treatment, in whom changes from 1 combination to another involved ≈1 in 10 patients after 6 months and 1 in 4 patients after 3 years (P<0.001 versus the group under monotherapy at each time-point). Figure 4 shows that, with respect to patients with initial monotherapy, patients prescribed an initial fixed-dose 2-drug combination (n=19 627) displayed a significant reduction in the risk of hospitalization for all considered outcomes. The risk reduction was largest for heart failure and smallest for cerebrovascular events, but for all events it was statistically significant
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Discussion
Our analysis of the data from the Lombardy population shows that patients starting antihypertensive treatment with a single drug do not move to combination treatment for years after treatment initiation, in striking contrast with the recommendation of guidelines to use combination treatment in most hypertensive patients 9 to take advantage of its superior ability to effectively lower BP 15 and achieve BP control. 16 It further shows that starting treatment with a combination of drugs can greatly reduce this inconvenience, leading to chronic use of antihypertensive drug combinations that remains for years much higher than that of the patients starting treatment with 1 drug only. Thus, in a real-life setting antihypertensive drug treatment is profoundly affected by an inertial attitude that opposes to an important degree treatment uptitration and is, therefore, likely to be majorly responsible for the low rate of hypertension control worldwide. 17 Inertia may be reduced by monitoring systems that provide frequent information and feedbacks on BP values, like those used for the Kaiser and Veterans Administration databases in the United States. 18, 19 However, this is difficult to be implemented in the general hypertensive population of most countries, in which, however avoiding the need to uptitrate treatment by an initial administration of 2 drugs might effectively cope with the problem, favoring long-term control of an elevated BP, as well as protection against hypertensionrelated complications. 20, 21 Indeed, confirming previous data from our group, 22 this was shown to occur in our patients in whom initial treatment with a fixed-dose 2-drug combination was associated during the 3-year follow-up with a significant and often marked reduction in the hospitalization for cause-specific cardiovascular outcomes, as well as for total cardiovascular outcomes and death, compared with initial treatment with a single drug.
In patients remaining on antihypertensive monotherapy during the follow-up, the percentage of treatment changes from one to another drug of the same or a different class increased with time, but it always involved a small fraction of the patients, ie, ≈15% and 30% after 6 months and 3 years of treatment, respectively. This means that not only do physicians unfrequently upgrade initial monotherapy to combination treatment but also that in most instances they stick to the drug originally prescribed, not even trying to move from one monotherapy to another to achieve the therapeutic BP goal. Antihypertensive treatment seems, therefore, to be dominated by a static attitude which favours the treatment originally prescribed, a conclusion that applies also to initial combination treatment which was changed from other 2-drug combinations of the same or other classes even less frequently than initial monotherapy, namely in only ≈10% and 25% of the patients after 6 months and 3 years, respectively. Thus, starting treatment with 2 drugs does not make therapeutic inertia less pronounced but simply bypasses the problem of moving from 1 to 2 antihypertensive drug prescription. Indeed, that inertia is a somewhat generalized phenomenon is further documented by the evidence that in both patients with initial monotherapy and in those with initial 2-drug combination therapy, uptitration to ≥3 antihypertensive drugs was much less frequent than that shown to be necessary in clinical trials. 23 Even on this count, however, initial combination treatment seems to carry some advantage because, although less frequent than that suggested by trials and guidelines, 9 the percentage of patients who were prescribed ≥3 drugs was greater for patients starting treatment with a 2-drug combination than for patients with initial monotherapy, that is, 17% and 9%, respectively.
In line with previous results, 2,3 no antihypertensive drug prescription was available during the follow-up in a considerable number of patients initially prescribed a single antihypertensive drug. This was the case, although to a lesser degree, also in patients initially prescribed a combination COPD indicates chronic obstructive pulmonary disease; and NSAIDs, nonsteroidal anti-inflammatory drugs.
*According to drug dispensed in the 8 y before the index prescription. †According to hospital admission in the 8 y before the index prescription.
therapy. This confirms that antihypertensive drug treatment is characterized by a high rate of treatment discontinuation, a phenomenon that can be reduced, but by no means eliminated, by initial use of 2 drugs and that this needs to be addressed by other means. 24 This is a medical priority because discontinuation leads to a fast return of BP to the originally elevated Figure 2 . Percentage of patients under 1, 2, and ≥3 antihypertensive drug prescription in the group prescribed initial monotherapy or 2-drug combination therapy, the drugs being given separately or as a fixed-dose single tablet. Data are shown for the sixth month and the first, second, and third year after the initial prescription date.
Figure 3.
Prevalence ratio (PR) for combination treatment (≥2 drugs) at various time-points during follow-up in patients initially prescribed monotherapy or a 2-drug combination therapy, the drugs being given separately or as a fixed-dose single tablet. Data were adjusted for baseline covariates (see Methods). The initial monotherapy group was taken as reference. At each time-point, the between-group difference was significant at P<0.001. values 25 and is accompanied by a marked increase of cardiovascular risk. 26, 27 Our data have strengths and weaknesses. As discussed in previous articles, 2, 3, 28 the strengths are that (1) the results reflect the entire Lombardy population because in Italy the National Health Service covers virtually all citizens; (2) data are accurate because pharmacists must file prescriptions to obtain reimbursement, and incorrect reports are legally persecuted; (3) the number of antihypertensive drug prescriptions outside the National Health Service database is trivial because cost of privately obtained prescriptions may be high and falls entirely on the patient; and (4) the results were not affected by differences in the prescribed drug classes because they were replicated by restricting the comparison of an initial combination between a blocker of the renin-angiotensin system and a diuretic with the corresponding drugs as initial monotherapy, thereby matching the drugs administered. The weaknesses are that (1) our healthcare utilization database includes a limited amount of clinical information and no BP values that may allow to relate different treatment strategies with BP control; (2) when data were analysed, reimbursement was extended to all antihypertensive monotherapies and combinations except for the fixed-dose combination between a blocker of the renin-angiotensin system and a calcium channel blocker. Thus, this now widely used fixed-dose combination was not part of the database; and (3) the results are likely to be representative for Italy, but extrapolation to other countries should be done with caution.
Perspectives
Our study provides evidence that in a real-life setting, longterm use of antihypertensive drug combinations is much higher in patients starting treatment with 2 drugs than in those starting treatment with 1 drug only, most of whom remain under monotherapy for years because of therapeutic inertia. Because combination treatment is needed for BP control in most hypertensive patients, this means that therapeutic inertia Data were adjusted for baseline covariates. The initial monotherapy group was taken as reference. Estimates were adjusted for covariates listed in Table 1 . P values refer to differences with the monotherapy group (Reference).
*Prevalence ratios estimated according to the log-binomial regression model. Hazard ratios (HR) and 95% CI estimating the risk of cardiovascular (CV) outcomes and death between patients with initial antihypertensive monotherapy and initial 2-drug fixed-dose combination therapy. Patients were initially matched by high-dimensional propensity score and outcomes were collected during the 3-year follow-up. The initial monotherapy group was taken as reference.
majorly contributes to the low rate of BP control that characterizes antihypertensive treatment worldwide and consequently to the incidence and risk of cardiovascular outcomes and death. Indeed this was documented in our study by the significantly lower risk of hospitalization for cardiovascular outcomes and mortality that was seen in patients under initial 2 antihypertensive drug combinations as compared with monotherapy. Thus, our findings provide strong support to a treatment strategy based on an initial 2-drug combination in most patients, as recommended by the recent United States and European guidelines.
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